Revvity Inc (RVTY)
割高ファンダメンタル
54
株価
$152.91
時価総額
$16.85B
パート1 · 企業の価値
概要
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$2.91B
直近12か月（2026/7/5まで）
純利益
$238M
直近12か月（2026/7/5まで）
フリーキャッシュフロー
$509M
自己資本合計
$7.25B
負債合計
$4.92B
流動比率
1.80
利払い倍率
3.82
負債/EBITDA
4.39
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$95.90
現在株価
$152.91
安全マージン
-59.4%
適正価値レンジ
$62.34 - $129.47
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
73.15
ROE
3.3%
P/B レシオ
2.36
P/FCF
30.57
粗利益率
-
ROIC
2.6%
収益性レーダー
価値創造（経済的モート）
ROIC
2.6%
WACC
9.2%
ROIC − WACC
-6.6 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（16）
- EPS shows upward trend
- Price CAGR 9.08%
- P/B Ratio 2.36
- Debt/Equity ratio
- Operating Margin 12.3%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Analyst Consensus 52% Buy
- Earnings Surprise avg 6.1%
- Earnings Quality (OCF/NI) 2.64
- Share Dilution -5.2%
- Piotroski F-Score 5/9
不合格（9）
- EPS CAGR 3.96%
- ROIC 2.6%
- P/FCF 30.57
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.3%
- Revenue Growth 5Y -5.5%
- Net Margin Trend 8.2% vs 10.2%
データなし（3）
- Gross Margin NaN%
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Dr. Prahlad R. Singh Ph.D. | CEO, President & Director | 60 |
| Mr. Maxwell Krakowiak | Senior VP & CFO | 35 |
| Mr. Tajinder S. Vohra | Senior Vice President of Global Operations | 59 |
| Mr. Joel S. Goldberg | Senior VP of Administration, General Counsel & Secretary | 56 |
| Ms. Miriame Victor | Senior Vice President & Chief Business Officer | 44 |
| Ms. Anita Gonzales | Chief Accounting Officer, VP & Controller | 49 |
| Mr. Bryan A. Kipp | Senior VP of Technology & Licensing | - |
| Dr. Madhuri Hegde FACMG, Ph.D. | Senior VP & Chief Scientific Officer | - |
| Mr. Stephen Barr Willoughby | Senior VP of Investor Relations & Head of ESG | - |
| Ms. Magali Four | Senior VP and Chief People & Culture Officer | - |
監査リスク
9
取締役会リスク
2
報酬リスク
8
株主権利リスク
4
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for RVTY, sourced from Markets Gazette.